The Covid vaccine functioned by introducing the virus into our bodies, thus encouraging them to build antibodies. It was the usual fighting fire with fire. Sometimes, however, antibodies fail to do their job when faced with the disease. They end up blocking other pathways instead, thus creating side effects and leaving us to fend for
Read More
Innovative biotech company AdAlta (ASX: 1AD) has been approved to commence human clinical trials for its next generation of protein therapeutics aimed at solving drug targeting problems commonly encountered in the sector. Approval has been granted by the Human Research Ethics Committee which enables AdAlta to commence recruiting healthy participants for trials of AD-214, their
Read More
Melbourne-based drug development company AdAlta (ASX: 1AD) has been selected by GE Healthcare, one of the world’s largest healthcare companies, to develop ‘i-bodies’ which GE can use as imaging agents. One-tenth of the size of regular antibodies, i-bodies are a new class of human protein therapeutic which can be applied as a therapeutic drug to
Read More